In the mid-1970s there were few prospects that injured tissues (except for bone and perhaps one or two others) might be guided down a regenerative pathway instead of following a default healing program resulting in scar. Biomaterials were generally of the permanent type, with no mention of absorbable scaffolds. It would be 20 years before tissue engineering and regenerative medicine would be discussed. There were no predicates, then, to inform the development of a biomaterial scaffold or matrix to facilitate a regenerative response in a tissue which would have otherwise healed by scar formation. It is all the more remarkable, then, that this was the time that work was beginning which would eventually lead to the development of a collagen device, the dermal regeneration template, that remains today a gold standard in the clinic for treating an array of skin injuries. And all the more notable is the fact that attendant to the development of the device were: the introduction of a method that would prove itself of value time and again for fabricating porous scaffolds; and the formulation of a concept (which has since become principle) underlying the regenerative process in many tissues. In reading the series of journal articles from the early 1980s describing the myriad laboratory tests and animal studies associated with the optimization of the design of the dermal regeneration template, one is struck by the logical and systematic approach and the thoroughness and rigor of the studies. The collective works are likely the first of their type to so thoroughly document the development of a biomaterial, and remain today a standard that is rarely met.
Aren't there some questions that you might have for the scientist-engineer responsible for what is one of the first developments of a clinically proven biomaterial scaffold from scratch? There were certainly many questions that I had, and this despite the fact I have taught and worked with him for 25 years, and consider myself his friend.
Ioannis Vassilios Yannas was born in Athens, Greece where he completed his high school education at Athens College. He received his AB degree in Chemistry at Harvard College, followed by the SM (1959) 
Myron Spector (MS):
After receiving your Master's degree in Chemical Engineering from MIT, you went to work for the company, W R Grace & Co., in Cambridge, MA for almost four years. What led you to decide to enter the PhD program at Princeton in Physical Chemistry?
Ioannis Vassilios Yannas (IVY):
In the early 1960s I had been working in an industrial laboratory on the synthesis and characterization of synthetic polymers. The field of synthetic polymers was reaching a mature level of development. There was a plethora of theories and experimental procedures available with which to study synthetic polymers. For many years I have had a keen interest in medicine. It occurred to me that the macromolecules of the tissues had not been studied at all using the methods of synthetic polymers. When I went to graduate school with an NIH Predoctoral Fellowship I started working with gelatin, the amorphous form of collagen, looking at it as a polymer in the solid state rather than as a biochemical substance.
MS:
Tell us more about your doctoral studies of gelatin.
IVY:
My first interest had been collagen due to its indispensable mechanical function in tissues. However, in order to study collagen as a polymer in the solid state I would have had to make collagen flow as a liquid in order to fashion appropriate specimens for mechanical measurements. This was not possible because collagen became unstable when heated above its melting point to become liquid like. I settled instead to a study of gelatin. In my thesis, gelatin proved to be the first protein to have its glass transition temperature determined (196
• C) and its viscoelastic behavior described. These measurements showed that polymers derived from tissues, such as proteins, could be studied by the methodology developed for synthetic polymers. Remember, in the 1960s people were distinguishing sharply between 'living' and nonliving polymers and such transfer of methodology from nonliving to the living had not been considered.
MS:
How did your work with collagen develop?
IVY:
After being appointed at the MIT faculty I started studying collagen as a polymer in the solid state, using all kinds of physicochemical methods. Two examples were optical rotation and an infrared spectroscopic method, both leading to determination of the ratio collagen/gelatin in the solid state. This ratio is a marker of denaturation of a collagenous product following exposure to unfavorable temperatures, e.g., during manufacturing of an industrial product. Since the degradation rate of collagen in the mammalian body increased sharply following denaturation to gelatin, this method was useful in controlling the degradation rate of a collagen product intended as an implant. Eventually several of these physicochemical methods became the basis for quality control for industrial products based on collagen, such as Integra TM .
MS: What led to your interest in studying skin?
IVY: During a visit to the Shriners Hospital in Boston with the head surgeon, Dr James Burke, I was struck by the misery of the pediatric patients who had sustained massive burns. I became engrossed in the wound healing processes of skin and started working on synthesis of membranes that would speed up the process of wound closure. After a large number of failures with synthetic polymers, we hit upon a membrane based on collagen that actually slowed down, rather than speed up, wound contraction (leading to wound closure) in guinea pigs. This unexpected result was not received with cheers by my medical colleagues; but it had to be understood because it was our first successful effort to control wound contraction (albeit along the wrong direction!). While looking carefully at histological slides of wounds that had closed abnormally slowly I noticed that these wounds did not have a scar, unlike all the other wounds we had studied. This happened in 1976. Eventually, this experience was recognized as the first observation of regeneration of the dermis in an adult mammal.
MS:
What was the thinking that led to adding glycosaminoglycan to modify the properties of the collagen?
IVY: Collagen and glycosaminoglycans (GAGs) were two macromolecules (elastin was a third polymer) known to make up the mass of most connective tissues. Our materials in the 1970s were planned as analogues of the extracellular matrix, which we modeled as fiber reinforced composite materials that were commonly studied by many materials scientists at that time. Our studies showed that GAGs, covalently linked to collagen, decreased the degradation rate of the biopolymers. This finding suggested that we could use the carbohydrate polymers to modulate degradation rate of implants. Although we were experimenting with crosslinking processes at that time as a means for controlling the degradation rate of implants, we thought that the binding of collagen with GAGs could be independently used to control degradation rate, thereby adding important design flexibility to collagen-based implants.
Another critical aspect of the performance of the collagen device was the introduction of porosity. What informed your implementation of freeze drying to produce a porous scaffold?
IVY: MIT colleagues in the, then, Department of Nutrition and Food Science, who were employing freeze drying in their work, brought our attention to that method. We then did a comparative study of freeze drying and other procedures, and found that freeze drying was the best for our purpose.
Tell us more about the thinking that underlies the development of the collagen-GAG biomaterial as a dermal regeneration template.
IVY:
The accidental discovery that a wound dressing that slowed down the rate of wound contraction was inducing dermis regeneration was central to our eventual development of the dermal regeneration template. Later studies showed that this template only induced regeneration if the pore size was controlled within the range 40-140 μm, the degradation half-life was 2-3 weeks and the surface chemistry possessed a very large density of ligands for integrins α1β1 and α2β1. These integrins are utilized by contractile fibroblasts for attachment to the extracellular matrix during wound contraction. These critical properties defined a scaffold capable of slowing down wound contraction by adhering on its extensive surface the contractile fibroblasts (myofibroblasts) of the healing wound. Cell adhesion on the scaffold surface inhibited greatly the normal ability of cells to adhere to each other during wound contraction, thereby canceling contraction. Cells adhered on the scaffold surface over a period of time, 2-3 weeks, during which the scaffold still persisted in an insoluble state. Scaffolds that were degraded before that period were totally inactive. This was the first demonstration of the mechanism by which an insoluble surface can possess remarkable biological activity.
MS:
What led to your investigation of peripheral nerve using the same principles that you applied to skin?
IVY:
A surgeon friend suggested to me in 1984 that we work together on problems related to the central nervous system, such as wound healing following a stroke affecting the brain. Since I was totally ignorant of the nervous system I suggested that we start working with peripheral nerves, considered by many to be easier to study than the brain and the spinal cord. Eventually, it turned out that peripheral nerves heal much as skin does except that the geometry is cylindrical rather than being planar. Wound contraction closes wounds in nerves as well as in skin and the same scaffolds that inhibit wound contraction and induce regeneration of skin turned out to do the same thing with nerves as well. This finding was tremendously satisfying to me. It suggested that the methodology of organ regeneration could potentially be applied to several organs.
MS:
What hope do you hold for biomaterial-based approaches to the treatment of other profound problems such as stroke and myocardial infarct?
IVY:
Each of these problems is a formidable exercise in science and engineering and must be approached with great respect for its complexity as well as with an appreciation of what has already been accomplished with skin and peripheral nerves.
MS:
You have been teaching biomaterials in the MIT graduate curricula for three decades. How has the course content and method for teaching the material changed in that time?
IVY:
The curriculum has changed as the instructors' experiences in the field have changed.
The emphasis is now not totally on permanent prostheses, such as the enormously useful hip implant. It has shifted markedly towards the applications of regenerative medicine to the huge medical problem of the organ with massively defective function.
MS:
Finally, can you tell us what you think about the future of the field?
IVY: Advances will emerge when it is understood that regeneration of organs in adults is a viable clinical treatment, inviting research on the mechanism and practice of regenerative medicine as applied to several organs. Several investigators have started using scaffolds related to our own in efforts to replace organ transplantation. These scaffolds, known as decellularized matrices, are obtained from unrelated donors. Their use is a strong indication that a collagen-based implant is the type of scaffold that can have an impact in regenerative medicine. Such an impact will not, I believe, be optimized until the structural features of the decellularized matrices are adjusted with respect to pore size, degradation rate and surface chemistry, along the direction shown by our quantitative studies with regeneration of skin and nerves.
Thanks so much, Yanni, for giving us these insights into seminal developments in biomaterials.
